Clinical trials: Central Line
Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD…
- Trial name
- NCT05567406
- Testing
- Belumosudil
- Sponsor
- Kadmon, a Sanofi Company
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Central Venous Catheter Placement
Comparison of Two Syringe-free In-plane Techniques in Ultrasound-guided Central Venous Catheterization
Ultrasound guidance has become a standard for central venous catheterization. The aim of this study is to compare jugular venous catheterization by using lateral oblique approach to brachiocephalic catheterization by using…
- Trial name
- NCT04256564
- Testing
- Central venous catheterization
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kutahya Health Sciences University
Chronic Graft-versus-host-disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
This study will be conducted to determine the clinical efficacy of axatilimab in Japanese participants with chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT06263478
- Testing
- INCA034176
- Where
- 16 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Incyte Biosciences Japan GK
Biliary Tract Cancer
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma
- Trial name
- NCT02966821
- Testing
- Surufatinib
- Where
- 5 sites in China
- Volunteers
- 39 people
- Sponsor
- Hutchison Medipharma Limited
Triple-negative Breast Cancer, Cadonilimab
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
The prognosis of recurrent and metastatic triple negative breast cancer (TNBC) is poor, and chemotherapy is still the main treatment for TNBC.
- Trial name
- NCT06367088
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Renal Cell Carcinoma
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a randomized, open-label, multi-center phase II study to…
- Trial name
- NCT02330783
- Testing
- Bevacizumab, Sorafenib
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastric Cancer, Bone Marrow Metastasis
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
A distinctive subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been described. Few patients have been treated properly due to the lack of standard care.
- Conditions
- Gastric Cancer, Bone Marrow Metastasis, Disseminated Intravascular Coagulation
- Trial name
- NCT04547153
- Testing
- 5-fluorouracil, Docetaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Liver metastasis is the main cause of death in patients with colorectal cancer. The treatment of liver metastasis of colorectal cancer is the key to prolong the survival of patients.
- Trial name
- NCT06423937
- Testing
- combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fudan University
Central Venous Catheter, Internal Jugular Vein
Correct Tip Position of Central Venous Catheters
Patients, ages between 18-70 years, who require central venous catheter will be enrolled for the study. Central venous catheter will be inserted using patient's height formula by Seldinger technique.
- Conditions
- Central Venous Catheter, Internal Jugular Vein, Radiography, Subclavian Vein Injury
- Trial name
- NCT05176886
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Bozyaka Training and Research Hospital
Central Line-associated Bloodstream Infection (CLABSI)
Determining the Prevalence of Primary and Secondary Central Line Associated Blood Stream Infection (CLABSI) at the Tertiary Care Hospital
Review key history and clinical examination findings of cases with CLABSI. Microbiological diagnosis and Culture sensitivity tests by automated Bact Alert and Vitek2c systems for CLABSI.
- Trial name
- Microbiology (NCT06458231)
- Testing
- Blood Catheters
- Where
- 2 sites in Egypt
- Volunteers
- 600 people
- Sponsor
- Port Said University
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Nephrostomy; Complications, Fistula
HoloStream Study - Video Capture Device Usage
Objectives: Primary Evaluate the primary operator usability of VSI streaming software for realtime streaming of images from video capture devices to a head mounted display (Hololens 2) during Interventional Radiology procedures…
- Conditions
- Nephrostomy; Complications, Fistula, Central Venous Catheter Thrombosis
- Trial name
- Holo-Stream (NCT04774588)
- Testing
- VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Spatial Neglect, Hemispatial Neglect
A Model to Identify Specific Predictors of Spatial Neglect Recovery
This study examines methods to better predict improvement of a hidden disability of functional vision, spatial neglect, following stroke.
- Conditions
- Spatial Neglect, Hemispatial Neglect, Hemineglect, Unilateral Neglect
- Trial name
- NCT00990353
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Kessler Foundation
Advanced NSCLC
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
Although some small sample studies have reported the possible resistance mechanisms of Osimertinib in the first-line treatment, it is still an urgent need to explore the whole gene profile in EGFRm advanced NSCLC patients post…
- Trial name
- GPS (NCT05219162)
- Testing
- Gene Profile explore
- Where
- 16 sites in China
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
NSCLC Stage IV, KRAS G12C
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
This study evaluates the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) of Glecirasib in combination with Ivonescimab in patients with previously…
- Trial name
- NCT07339839
- Testing
- Glecirasib, Ivonescimab
- Volunteers
- 42 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unresectable Metastatic Colorectal Cancer
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients…
- Trial name
- NCT04866108
- Testing
- fruquintinib plus capecitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Friendship Hospital
Falls Injury, Readmission Rates
Duke Virtual IntEgrated Workflow
This quality improvement initiative aims to evaluate the implementation, utilization, and impact of virtual care technologies and workflows being implemented at Duke University Health System (DUHS).
- Conditions
- Falls Injury, Readmission Rates, CLABSI - Central Line Associated Bloodstream Infection, Catheter Associated Urinary Tract Infection
- Trial name
- Duke VIEW (NCT07406074)
- Testing
- Co-Care
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Duke University
Patients With Moderate to Severe Perioral Lines
JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
A prospective, randomized, controlled, multi-center study of the safety and effectiveness of JUVEDERM® Ultra XC injectable gel versus Belotero Balance® for perioral lines
- Trial name
- NCT01970397
- Testing
- JUVEDERM® Ultra XC, Belotero Balance®
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Allergan
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals